Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

Similar articles for PubMed (Select 20385363)

1.

Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth.

Kim J, Tang JY, Gong R, Kim J, Lee JJ, Clemons KV, Chong CR, Chang KS, Fereshteh M, Gardner D, Reya T, Liu JO, Epstein EH, Stevens DA, Beachy PA.

Cancer Cell. 2010 Apr 13;17(4):388-99. doi: 10.1016/j.ccr.2010.02.027.

2.

A functional and putative physiological role of calcitriol in Patched1/Smoothened interaction.

Linder B, Weber S, Dittmann K, Adamski J, Hahn H, Uhmann A.

J Biol Chem. 2015 Jun 30. pii: jbc.M115.646141. [Epub ahead of print]

3.

AT-101 inhibits hedgehog pathway activity and cancer growth.

Wang J, Peng Y, Liu Y, Yang J, Huang M, Tan W.

Cancer Chemother Pharmacol. 2015 Jun 26. [Epub ahead of print]

PMID:
26113054
4.

Biochemical characterization of smoothened receptor antagonists by binding kinetics against drug-resistant mutant.

Shimizu Y, Ishii T, Ogawa K, Sasaki S, Matsui H, Nakayama M.

Eur J Pharmacol. 2015 Jun 2. pii: S0014-2999(15)30062-5. doi: 10.1016/j.ejphar.2015.05.062. [Epub ahead of print]

PMID:
26048307
5.

Repurposing Drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent.

Pantziarka P, Sukhatme V, Bouche G, Meheus L, Sukhatme VP.

Ecancermedicalscience. 2015 Apr 15;9:521. doi: 10.3332/ecancer.2015.521. eCollection 2015.

6.

Molecular docking approaches in identification of High affinity inhibitors of Human SMO receptor.

Akare UR, Bandaru S, Shaheen U, Singh PK, Tiwari G, Singare P, Nayarisseri A, Banerjee T.

Bioinformation. 2014 Dec 31;10(12):737-42. doi: 10.6026/97320630010737. eCollection 2014.

7.

The Hedgehog pathway effector smoothened exhibits signaling competency in the absence of ciliary accumulation.

Fan CW, Chen B, Franco I, Lu J, Shi H, Wei S, Wang C, Wu X, Tang W, Roth MG, Williams NS, Hirsch E, Chen C, Lum L.

Chem Biol. 2014 Dec 18;21(12):1680-9. doi: 10.1016/j.chembiol.2014.10.013. Epub 2014 Dec 4. Erratum in: Chem Biol. 2015 Apr 23;22(4):559.

PMID:
25484239
8.

Design, synthesis, and structure--activity-relationship of tetrahydrothiazolopyridine derivatives as potent smoothened antagonists.

Ma H, Lu W, Sun Z, Luo L, Geng D, Yang Z, Li E, Zheng J, Wang M, Zhang H, Yang S, Zhang X.

Eur J Med Chem. 2015 Jan 7;89:721-32. doi: 10.1016/j.ejmech.2014.11.006. Epub 2014 Nov 4.

PMID:
25462278
9.

Basal cell carcinoma, Hedgehog signaling, and targeted therapeutics: the long and winding road.

Wong SY, Dlugosz AA.

J Invest Dermatol. 2014 Oct 10;134(e1):E18-22. doi: 10.1038/skinbio.2014.4. Review. No abstract available.

PMID:
25302468
10.

Recent advances in the design of Hedgehog pathway inhibitors for the treatment of malignancies.

Banerjee U, Hadden MK.

Expert Opin Drug Discov. 2014 Jul;9(7):751-71. doi: 10.1517/17460441.2014.920817. Epub 2014 May 22. Review.

PMID:
24850423
11.

Activation of liver X receptors inhibits hedgehog signaling, clonogenic growth, and self-renewal in multiple myeloma.

Agarwal JR, Wang Q, Tanno T, Rasheed Z, Merchant A, Ghosh N, Borrello I, Huff CA, Parhami F, Matsui W.

Mol Cancer Ther. 2014 Jul;13(7):1873-81. doi: 10.1158/1535-7163.MCT-13-0997. Epub 2014 May 7.

12.

Vismodegib.

Meiss F, Zeiser R.

Recent Results Cancer Res. 2014;201:405-17. doi: 10.1007/978-3-642-54490-3_25. Review.

PMID:
24756807
13.

Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer.

Brechbiel J, Miller-Moslin K, Adjei AA.

Cancer Treat Rev. 2014 Jul;40(6):750-9. doi: 10.1016/j.ctrv.2014.02.003. Epub 2014 Feb 24. Review.

PMID:
24613036
14.

Impact of the Smoothened inhibitor, IPI-926, on smoothened ciliary localization and Hedgehog pathway activity.

Peluso MO, Campbell VT, Harari JA, Tibbitts TT, Proctor JL, Whitebread N, Conley JM, White KF, Kutok JL, Read MA, McGovern K, Faia KL.

PLoS One. 2014 Mar 7;9(3):e90534. doi: 10.1371/journal.pone.0090534. eCollection 2014.

15.

Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma.

Kim DJ, Kim J, Spaunhurst K, Montoya J, Khodosh R, Chandra K, Fu T, Gilliam A, Molgo M, Beachy PA, Tang JY.

J Clin Oncol. 2014 Mar 10;32(8):745-51. doi: 10.1200/JCO.2013.49.9525. Epub 2014 Feb 3.

16.

Hedgehog signaling pathway is a potential therapeutic target for gallbladder cancer.

Matsushita S, Onishi H, Nakano K, Nagamatsu I, Imaizumi A, Hattori M, Oda Y, Tanaka M, Katano M.

Cancer Sci. 2014 Mar;105(3):272-80. doi: 10.1111/cas.12354. Epub 2014 Feb 18.

PMID:
24438533
17.

Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.

Proctor AE, Thompson LA, O'Bryant CL.

Ann Pharmacother. 2014 Jan;48(1):99-106. doi: 10.1177/1060028013506696. Epub 2013 Oct 15. Review.

PMID:
24259609
18.

PTEN loss mitigates the response of medulloblastoma to Hedgehog pathway inhibition.

Metcalfe C, Alicke B, Crow A, Lamoureux M, Dijkgraaf GJ, Peale F, Gould SE, de Sauvage FJ.

Cancer Res. 2013 Dec 1;73(23):7034-42. doi: 10.1158/0008-5472.CAN-13-1222. Epub 2013 Oct 23.

19.

Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.

You M, Varona-Santos J, Singh S, Robbins DJ, Savaraj N, Nguyen DM.

J Thorac Cardiovasc Surg. 2014 Jan;147(1):508-16. doi: 10.1016/j.jtcvs.2013.08.035. Epub 2013 Oct 4.

PMID:
24094913
20.

LKB1 inhibits breast cancer partially through repressing the Hedgehog signaling pathway.

Zhuang Z, Wang K, Cheng X, Qu X, Jiang B, Li Z, Luo J, Shao Z, Duan T.

PLoS One. 2013 Jul 4;8(7):e67431. doi: 10.1371/journal.pone.0067431. Print 2013.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk